Companies › Hummingbird Bioscience
2 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HMBD-501 HER3-targeted antibody-drug conjugate | ERBB3 | Phase 1 | Melanoma (Skin) | Jul 2027 |
| HMBD-001 Anti-HER3 monoclonal antibody | ERBB3 | Phase 1 | Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Bladder Cancer | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05057013 | HMBD-001 | Phase 1 | Bladder Cancer | Oncology | Nov 2025 |
| NCT06956690 | HMBD-501 | Phase 1 | Melanoma (Skin) | Oncology | Jul 2027 |
| NCT05910827 | HMBD-001 | Phase 1 | Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT05919537 | HMBD-001 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Mar 2031 |
Shanghai Institute Of Biological Products Daiichi Sankyo Salubris Biotherapeutics Merck & Co. (MSD) Partner Therapeutics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.